European Union´s Horizon 2020 – Lipum2019-07-05T11:00:21+00:00


Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

1812, 2019

A milestone has been reached

December 18th, 2019|

After an intensive and targeted work, the cell line development of our lead drug candidate SOL-116 has been finalized. Now the production optimization and scale up has been initiated and that will provide access of non-GMP and GMP material during 2020. That will enable toxicity studies and start of clinical [...]

2611, 2019

Pharma Outsourcing 2019

November 26th, 2019|

“How we selected our CMO partner for cell line and production development of Lipum´s lead candidate drug SOL-116” […]

1510, 2019

BioStock Life Science Summit

October 15th, 2019|

Life Science industry leaders, financing experts and qualified investors gather in Lund. Welcome to meet us at Biostock Life Science Summit, october 23th-24th. […]

3009, 2019

Lipum participates in investment and partnering meeting

September 30th, 2019|

Today, our COO, Pernilla Abrahamsson, is traveling to Paris to participate at French-Swedish Life Science Days 2019. The goal of the conference is to establish new contacts and identify business and collaboration opportunities. The conference will gather early stage and highly innovative medtech and biotech companies from Sweden and France, [...]

1909, 2019

Lipum to Basel for one-to-one meetings

September 19th, 2019|

- We are looking forward to one-to-one meetings in Basel, among the largest biopharma hubs in Europe, says CEO Einar Pontén when Lipum is preparing to participate at the 19th Annual Biotech in Europe Forum (Sachs) on September 25-26.

European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€